Treatment with lenvatinib, a multikinase inhibitor targeting receptors for vascular endothelial growth factor, FGF, and platelet-derived growth factor, improves progression-free survival in patients with advanced thyroid cancer and iodine-refractory differentiated thyroid cancer [31], and shows anti-angiogenic effects involving inhibition of FGFR signaling [61,62]. This evidence concerns the gene VEGFA and thyroid gland carcinoma.